Early Diagnosis and Screening for Lung Cancer
- 17 May 2021
- journal article
- research article
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Perspectives in Medicine
- Vol. 11 (9), a037994
- https://doi.org/10.1101/cshperspect.a037994
Abstract
Cancer interception refers to actively blocking the cancer development process by preventing progression of premalignancy to invasive disease. The rate-limiting steps for effective lung cancer interception are the incomplete understanding of the earliest molecular events associated with lung carcinogenesis, the lack of preclinical models of pulmonary premalignancy, and the challenge of developing highly sensitive and specific methods for early detection. Recent advances in cancer interception are facilitated by developments in next-generation sequencing, computational methodologies, as well as the renewed emphasis in precision medicine and immuno-oncology. This review summarizes the current state of knowledge in the areas of molecular abnormalities in lung cancer continuum, preclinical human models of lung cancer pathogenesis, and the advances in early lung cancer diagnostics.Keywords
This publication has 144 references indexed in Scilit:
- Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and ErlotinibClinical Cancer Research, 2012
- Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic ScreeningThe New England Journal of Medicine, 2011
- EMT and Stem Cell–Like Properties Associated with miR-205 and miR-200 Epigenetic Silencing Are Early Manifestations during Carcinogen-Induced Transformation of Human Lung Epithelial CellsCancer Research, 2011
- Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancerBritish Journal of Cancer, 2011
- Evolving Concepts in Lung CarcinogenesisSeminars in Respiratory and Critical Care Medicine, 2011
- The National Lung Screening Trial: Overview and Study DesignRadiology, 2011
- Progressive 3q Amplification Consistently Targets SOX2 in Preinvasive Squamous Lung CancerAmerican Journal of Respiratory and Critical Care Medicine, 2010
- SOX2 Is an Oncogene Activated by Recurrent 3q26.3 Amplifications in Human Lung Squamous Cell CarcinomasPLOS ONE, 2010
- SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomasNature Genetics, 2009
- Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor‐specific fluorescent ligandsInternational Journal of Cancer, 2008